Overview

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences